Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
comunicado de prensa Trasplante de órganos: ALS obtiene el marcado CE para PERLA®, una nueva clase de solución – PPS – desarrollada junto al IDIBAPS (Barcelona), y lanza un estudio clínico...
-
COMMUNIQUÉ DE PRESSE Transplantation d’organes : ALS obtient le marquage CE pour PERLA®, une nouvelle classe de solution - PPS - et lance une étude clinique comparative Obtention du marquage CE...
-
Press Release Organ transplantation: ALS achieved CE Certification for PERLA®, The new class of solution – PPS – and launches a randomized comparative clinical trial (RCT) ALS has received CE...
-
Positive P2b trial results on naronapride show significant, meaningful impact on gastroparesis symptoms; with favorable safety and tolerability profiles.
-
Confo Therapeutics announces the Phase 2a clinical trial initiation by Eli Lilly and Company for CFTX-1554 in peripheral pain.
-
Funds will support one of the largest interventional clinical trials of a full-spectrum microbiome product, and the largest ever to be conducted in IBSDosing of first patient of the Phase 2b ‘RISE’...
-
Funds will support one of the largest interventional clinical trials of a full-spectrum microbiome product, and the largest ever to be conducted in IBSDosing of first patient of the Phase 2b ‘RISE’...
-
Prodeon at AUA 2026: Urocross Expander pivotal RCT to be presented at the plenary: 30-month data shows durable BPH relief and preserved sexual function
-
TOKYO and SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) and Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) today announced the first patient has been...
-
EXECUTIVE SUMMARY final European scientific advice received for pivotal Phase III vitiligo studyEMA emphasised its “totality of evidence” approachcentral photographic review and validated disease...